MedTrace Logo

Effect of Irbesartan on Insulin Sensitivity in Chronic Heart Failure

NCT00347087 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2007-10-31

No results posted yet for this study

Summary

To test whether treatment with the angiotensin II receptor antagonist Irbesartan improves insulin sensitivity and metabolic profile in patients with chronic heart failure.

Conditions

Interventions

DRUG

Irbesartan

up-titration over 4 weeks to target dose 300 mg od

Sponsors & Collaborators

Principal Investigators

  • Wolfram Doehner, MD, PhD · Applied Cachexia Research, Cardiology, Charite, Campus Virchow Klinikum

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-07-31
Completion
2007-06-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00347087 on ClinicalTrials.gov